

Alfredo Budillon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5425414/publications.pdf>

Version: 2024-02-01

191
papers

7,529
citations

38742

50
h-index

64796

79
g-index

200
all docs

200
docs citations

200
times ranked

13108
citing authors

#	ARTICLE	IF	CITATIONS
1	An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 646.	3.7	5
2	Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors. <i>Cancers</i> , 2022, 14, 695.	3.7	3
3	Metabolomics for oncology. , 2022, , 553-604.		0
4	HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 83.	8.6	19
5	Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	25
6	HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer. <i>Molecular Oncology</i> , 2021, 15, 1005-1023.	4.6	8
7	Golgi maturation-dependent glycoenzyme recycling controls glycosphingolipid biosynthesis and cell growth via GOLPH3. <i>EMBO Journal</i> , 2021, 40, e107238.	7.8	45
8	NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. <i>Journal of Biomedical Science</i> , 2021, 28, 26.	7.0	62
9	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2118475.	5.9	16
10	Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10177.	4.1	35
11	A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. <i>Journal of Clinical Medicine</i> , 2021, 10, 136.	2.4	12
12	Large extracellular vesicles: Size matters in tumor progression. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 69-74.	7.2	41
13	Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 213.	8.6	26
14	New Prognostic and Predictive Markers in Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8667.	4.1	9
15	Targeting Autophagy in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7836.	4.1	54
16	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i> -mutated metastatic colorectal cancer: the REVOLUTION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092958.	3.2	10
17	Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6694.	4.1	4
18	Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 732.	3.7	22

#	ARTICLE	IF	CITATIONS
19	Outcome Prediction of Metastatic Colorectal Cancer Patients Undergoing Liver Resection after Neoadjuvant Chemotherapy by Analyzing Serum Metabolomics and Cytokinomics.. European Journal of Surgical Oncology, 2020, 46, e94.	1.0	0
20	Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma. Cells, 2020, 9, 1062.	4.1	11
21	Abstract 5223: Valproic acid, by preventing cisplatin/cetuximab-induced EGFR nuclear translocation and increasing cisplatin uptake, potentiates the antitumor effect of the combination treatment in head and neck squamous cell carcinomas. , 2020, , .		0
22	Abstract 5270: HSP90 identified by a proteomic approach as druggable target to reverse platinum-resistance in ovarian cancer. , 2020, , .		0
23	Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation. Journal of Experimental and Clinical Cancer Research, 2019, 38, 317.	8.6	82
24	Identification and Targeting of Stem Cell-Activated Pathways in Cancer Therapy. Stem Cells International, 2019, 2019, 1-2.	2.5	8
25	Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.. Journal of Clinical Medicine, 2019, 8, 912.	2.4	36
26	Structural analysis of human SEPHS2 protein, a selenocysteine machinery component, over-expressed in triple negative breast cancer. Scientific Reports, 2019, 9, 16131.	3.3	19
27	Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity. Scientific Reports, 2019, 9, 12169.	3.3	11
28	Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake. Molecular Cancer Therapeutics, 2019, 18, 1405-1417.	4.1	18
29	Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3 ^β -MCL-1 Axis. Cancer Cell, 2019, 35, 798-815.e5.	16.8	212
30	¹⁸ F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer. Journal of Nuclear Medicine, 2019, 60, 1560-1568.	5.0	18
31	Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 393-409.	2.5	25
32	Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-small cell lung cancer cells. Journal of Cellular Physiology, 2019, 234, 9077-9092.	4.1	11
33	Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death and Differentiation, 2019, 26, 1267-1282.	11.2	47
34	Abstract P4-07-09: Role played by autophagy in breast cancer models exposed to new PI3K/AKT inhibitors, GDC-0068 and GDC-0032. , 2019, , .		0
35	Abstract 5268: Outcome prediction of metastatic colorectal cancer patients undergoing liver resection by analyzing serum metabolomics. , 2019, , .		0
36	A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. Scientific Reports, 2018, 8, 5823.	3.3	38

#	ARTICLE	IF	CITATIONS
37	Effects of $\hat{1}\pm$ -zearalenol on the metabolome of two breast cancer cell lines by 1H-NMR approach. <i>Metabolomics</i> , 2018, 14, 33.	3.0	16
38	Toxicogenic effects of two benthic diatoms upon grazing activity of the sea urchin: morphological, metabolomic and de novo transcriptomic analysis. <i>Scientific Reports</i> , 2018, 8, 5622.	3.3	28
39	Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE). <i>Annals of Oncology</i> , 2018, 29, viii203.	1.2	1
40	Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE). <i>Annals of Oncology</i> , 2018, 29, viii202.	1.2	0
41	Survival analysis of a multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2018, 29, v74.	1.2	0
42	The Crosstalk between Cancer Stem Cells and Microenvironment Is Critical for Solid Tumor Progression: The Significant Contribution of Extracellular Vesicles. <i>Stem Cells International</i> , 2018, 2018, 1-11.	2.5	31
43	Evaluation of Aflatoxin M1 Effects on the Metabolomic and Cytokinomic Profiling of a Hepatoblastoma Cell Line. <i>Toxins</i> , 2018, 10, 436.	3.4	10
44	Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 184-200.	1.6	83
45	The Effect of Light Exposure at Night (LAN) on Carcinogenesis via Decreased Nocturnal Melatonin Synthesis. <i>Molecules</i> , 2018, 23, 1308.	3.8	25
46	Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers. <i>Scientific Reports</i> , 2018, 8, 10395.	3.3	7
47	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018, 16, .	4.4	2
48	Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3562-3562.	1.6	0
49	Abstract 2877: Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting cancer stem cells compartment via YAP-pathway modulation. , 2018, , .		1
50	Abstract B10: HDAC inhibition modulates immune checkpoint pathway in triple-negative breast cancer. , 2018, , .		0
51	Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. <i>Oncogene</i> , 2017, 36, 4573-4584.	5.9	123
52	Conformational analysis of the human chemokine receptor CXCR3. <i>Molecular Immunology</i> , 2017, 92, 76-86.	2.2	1
53	An interaction network approach to study the correlation between endocrine disrupting chemicals and breast cancer. <i>Molecular BioSystems</i> , 2017, 13, 2687-2696.	2.9	0
54	Synthesis and Evaluation of the Antitumor Properties of a Small Collection of Pt^{II} Complexes with 7â€œDeazaadenosine as Scaffold. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 4935-4947.	2.4	10

#	ARTICLE	IF	CITATIONS
55	Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. <i>Amino Acids</i> , 2017, 49, 517-528.	2.7	9
56	Optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC): the multicentre, randomized phase 3 study OBELICS. <i>Annals of Oncology</i> , 2017, 28, vi5.	1.2	2
57	HDAC inhibition potentiates immunotherapy in triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 114156-114172.	1.8	139
58	Evaluating the Effects of an Organic Extract from the Mediterranean Sponge <i>Geodia cydonium</i> on Human Breast Cancer Cell Lines. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2112.	4.1	17
59	Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-18.	4.0	102
60	Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 177.	8.6	33
61	Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis. <i>PLoS ONE</i> , 2017, 12, e0169462.	2.5	10
62	Environment and bladder cancer: molecular analysis by interaction networks. <i>Oncotarget</i> , 2017, 8, 65240-65252.	1.8	39
63	Synthesis of Arylpiperazine Derivatives as Protease Activated Receptor 1 Antagonists and Their Evaluation as Antiproliferative Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2017, 17, 973-981.	1.7	0
64	Abstract 4058: Preclinical and phase-2 clinical study of valproic acid administered in combination with cisplatin and cetuximab in recurrent/metastatic head and neck cancer. , 2017, , .		1
65	Potential Anticancer Effects of Polyphenols from Chestnut Shell Extracts: Modulation of Cell Growth, and Cytokinomic and Metabolomic Profiles. <i>Molecules</i> , 2016, 21, 1411.	3.8	57
66	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1564-1564.	1.6	5
67	Biotin-targeted Pluronic Â® P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cells. <i>International Journal of Pharmaceutics</i> , 2016, 511, 127-139.	5.2	71
68	Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. <i>BMC Cancer</i> , 2016, 16, 918.	2.6	60
69	Proteomic characterization of peroxisome proliferator-activated receptor-Î³ (PPARÎ³) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype. <i>Molecular Oncology</i> , 2016, 10, 1344-1362.	4.6	16
70	Management of non-small cell lung cancer in the era of personalized medicine. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 78, 173-179.	2.8	25
71	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQq1 1 2017 843148 BT / Oncotarget	1.2	2
72	Endothelial progenitor cells, defined by the simultaneous surface expression of <sc>VEGFR</sc>2 and <sc>CD</sc>133, are not detectable in healthy peripheral and cord blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 259-270.	1.5	51

#	ARTICLE	IF	CITATIONS
73	Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. <i>Cell Death and Disease</i> , 2016, 7, e2120-e2120.	6.3	65
74	The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells. <i>Cell Death and Disease</i> , 2016, 7, e2108-e2108.	6.3	58
75	Enhancement of 5-FU sensitivity by the proapoptotic rpl3 gene in p53 null colon cancer cells through combined polymer nanoparticles. <i>Oncotarget</i> , 2016, 7, 79670-79687.	1.8	44
76	Valproic acid potentiates the anticancer activity of capecitabine <i>in vitro</i> and <i>in vivo</i> in breast cancer models via induction of thymidine phosphorylase expression. <i>Oncotarget</i> , 2016, 7, 7715-7731.	1.8	67
77	Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. <i>Oncotarget</i> , 2016, 7, 19559-19574.	1.8	20
78	Abstract 1052: Stearoyl-CoA-Desaturase (SCD1) regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. , 2016, , .		0
79	Abstract 4745: Repurposing of valproic acid and simvastatin combination as anticancer agents in prostate cancer: synergistic interaction with docetaxel and suppression of docetaxel resistance. , 2016, , .		0
80	Abstract B111: HDAC inhibitors modulate immune checkpoint blockade in breast cancer. , 2016, , .		0
81	Synergistic antitumor interaction between valproic acid and capecitabine in breast cancer. , 2015, 3, P4.		0
82	Synthesis and Evaluation of the Antiproliferative Properties of a Tethered Tubercidin-Platinum(II) Complex. <i>European Journal of Organic Chemistry</i> , 2015, 2015, 7550-7556.	2.4	6
83	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015, 21, 795-801.	30.7	809
84	A perspective on the current treatment strategies for locally advanced rectal cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 65, 192-196.	2.8	3
85	Pathophysiologically relevant <i>in vitro</i> tumor models for drug screening. <i>Drug Discovery Today</i> , 2015, 20, 848-855.	6.4	54
86	Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway. <i>Free Radical Biology and Medicine</i> , 2015, 89, 287-299.	2.9	73
87	Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype. <i>Oncotarget</i> , 2015, 6, 5324-5341.	1.8	20
88	Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial. <i>Oncotarget</i> , 2015, 6, 30394-30407.	1.8	44
89	Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. <i>Oncotarget</i> , 2015, 6, 25074-25092.	1.8	53
90	Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11073-11073.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients. , 2015, , .		0
92	Abstract 4154: Large oncosomes derived from the aggressive prostate cancer sub-line, DU145R80, can modify the biological behavior of the parental DU145 cells. , 2015, , .		0
93	Abstract 2569: Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer as a rationale for the innovative V-shoRT-R3 trial in locally advanced rectal cancer patients. , 2015, , .		0
94	Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle, 2014, 13, 652-665.	2.6	36
95	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum) Tj ETQq1 1 0z784314 rgBT /Overlock 10 T	2.8	14
96	Exposure to Perfluoroalkyl Substances and Sperm DNA Global Methylation in <scp>Arctic</scp> and <scp>European</scp> Populations. Environmental and Molecular Mutagenesis, 2014, 55, 591-600.	2.2	45
97	New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent. Cancer Treatment and Research, 2014, 159, 355-376.	0.5	119
98	Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opinion on Drug Safety, 2014, 13, 113-129.	2.4	30
99	Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research, 2014, 74, 3408-3417.	0.9	101
100	Indices of methylation in sperm DNA from fertile men differ between distinct geographical regions. Human Reproduction, 2014, 29, 2065-2072.	0.9	20
101	Abstract 5311: Proteomic characterization of zoledronic acid-resistant prostate cancer cells identified key proteins in cytoskeleton organization and cancer stem cell markers associated with a very aggressive phenotype. , 2014, , .		0
102	Abstract 5444: Modulation of ErbB receptors expression by histone deacetylase inhibitors increased the antitumor activity of an anti-ErbB3 monoclonal antibody in primary cultures from non-small cell lung cancer patients. , 2014, , .		0
103	Tissue transglutaminase: a new target to reverse cancer drug resistance. Amino Acids, 2013, 44, 63-72.	2.7	52
104	Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death and Disease, 2013, 4, e641-e641.	6.3	57
105	Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death and Disease, 2013, 4, e878-e878.	6.3	50
106	Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 852-860.	1.7	14
107	Abstract 4695: Predictive role of FDG PET-CT in monitoring locally advanced rectal cancer (LARC) during preoperative radiochemotherapy with an experimental bevacizumab schedule.. , 2013, , .		0
108	Editorial [Hot Topic: Pancreatic Cancer: Between Bench and Bedside (Guest Editors: Davide Melisi and) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.1	10

#	ARTICLE	IF	CITATIONS
109	Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1848-1857.	6.4	53
110	The Primary Occurrence of <i>BRAF</i> ^{V600E} Is a Rare Clonal Event in Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 517-524.	3.6	134
111	A High Percentage of <i>BRAF</i> ^{V600E} Alleles in Papillary Thyroid Carcinoma Predicts a Poorer Outcome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2333-2340.	3.6	112
112	Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/β-catenins complex and multiple <i>erbB</i> receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas. <i>Journal of Cellular Physiology</i> , 2012, 227, 3344-3353.	4.1	40
113	The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-γ treated pancreatic cancer cells. <i>Biotechnology Advances</i> , 2012, 30, 169-184.	11.7	76
114	Abstract LB-219: Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers.. , 2012, , .		1
115	Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype. <i>Clinical Cancer Research</i> , 2011, 17, 5822-5832.	7.0	86
116	Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. <i>Proteomics</i> , 2011, 11, 3725-3742.	2.2	21
117	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. <i>Journal of Cellular Physiology</i> , 2011, 226, 2378-2390.	4.1	139
118	Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 341-353.	2.6	29
119	Oxaliplatin Plus Dual Inhibition of Thymidilate Synthase During Preoperative Pelvic Radiotherapy for Locally Advanced Rectal Carcinoma: Long-Term Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 670-676.	0.8	25
120	Synthesis of 1-naphthylpiperazine derivatives as serotonergic ligands and their evaluation as antiproliferative agents. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 2206-2216.	5.5	11
121	Modulation of Pancreatic Cancer Chemoresistance by Inhibition of TAK1. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1190-1204.	6.3	137
122	Histone Deacetylase Inhibitors in Cancer Therapy. , 2011, , 79-115.		0
123	Abstract 3519: Histone deacetylase inhibitors upregulates thymidine phosphorylase gene and protein expression and synergize with capecitabine in breast cancer cells. <i>Cancer Research</i> , 2011, 71, 3519-3519.	0.9	1
124	Abstract 3287: Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT. , 2011, , .		0
125	Abstract 2609: Tissue transglutaminase (TG2) promotes resistance to HDAC inhibitor (HDI) vorinostat in cancer cells. , 2011, , .		0
126	Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. <i>British Journal of Cancer</i> , 2010, 103, 1680-1691.	6.4	42

#	ARTICLE	IF	CITATIONS
127	Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2010, 5, 1-13.	1.6	18
128	Metronomic administration of Zoledronic Acid and Taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. <i>Cancer Biology and Therapy</i> , 2010, 10, 543-548.	3.4	44
129	Abstract 3721: Critical role of Bevacizumab schedule in combination with chemo-radiotherapy in neo-adjuvant treatment of rectal cancer: Circulating endothelial cells and FDG-PET as markers for early prediction. , 2010, , .		0
130	Abstract 5442: In vitro and in vivo upregulation of thymidine phosphorylase expression in colon cancer cells by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with capecitabine. , 2010, , .		0
131	Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed. <i>Cancer Biology and Therapy</i> , 2009, 8, 782-791.	3.4	65
132	Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3075-3087.	4.1	104
133	Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. <i>International Journal of Cancer</i> , 2009, 125, 2004-2013.	5.1	31
134	Locally Advanced Rectal Cancer: Combined Chemotherapy During Preoperative Radiation Therapy. , 2009, , 411-436.		2
135	The Multidrug Transporter P-Glycoprotein: A Mediator of Melanoma Invasion?. <i>Journal of Investigative Dermatology</i> , 2008, 128, 957-971.	0.7	91
136	Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 79-85.	2.2	7
137	A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology. <i>Annals of Oncology</i> , 2007, 18, 960-961.	1.2	2
138	Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan. <i>Annals of Oncology</i> , 2007, 18, 1579-1580.	1.2	1
139	Adenylate Cyclase/cAMP Pathway Downmodulation Counteracts Apoptosis Induced by IFN- γ in Human Epidermoid Cancer Cells. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 129-136.	1.2	13
140	Phase II studies of anticancer chemotherapy: indirect evidence of poor quality. <i>Annals of Oncology</i> , 2007, 18, 403.	1.2	2
141	Concomitant Occurrence of Facial Cutaneous and Parotid Gland Metastases from Rectal Cancer after Preoperative Chemoradiotherapy. <i>Oncology Research and Treatment</i> , 2007, 30, 324-326.	1.2	3
142	Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours. <i>Current Signal Transduction Therapy</i> , 2007, 2, 165-173.	0.5	0
143	Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. <i>Anti-Cancer Drugs</i> , 2007, 18, 781-791.	1.4	15
144	The farnesyltransferase inhibitor R115777 (ZARNESTRAA [®]) enhances the proapoptotic activity of interferon- γ through the inhibition of multiple survival pathways. <i>International Journal of Cancer</i> , 2007, 121, 2317-2330.	5.1	21

#	ARTICLE	IF	CITATIONS
145	R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. <i>Journal of Cellular Physiology</i> , 2007, 211, 533-543.	4.1	57
146	The immunomodulatory protein SV40 protects serum-deprived cells against apoptosis but not against G0/G1 arrest: Possible implications for the survival of implanting embryo. <i>Journal of Cellular Physiology</i> , 2007, 212, 610-625.	4.1	6
147	C-Raf antagonizes apoptosis induced by IFN- γ in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. <i>Cell Death and Differentiation</i> , 2007, 14, 952-962.	11.2	48
148	Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 1095-1106.	4.1	133
149	Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract. <i>Amino Acids</i> , 2007, 32, 395-400.	2.7	9
150	Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products. <i>Amino Acids</i> , 2007, 33, 273-281.	2.7	6
151	Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 119-134.	1.6	51
152	Cetuximab is an active treatment of metastatic and chemorefractory thymoma. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 757.	3.0	70
153	Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 383-396.	1.6	28
154	Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase II study. <i>British Journal of Cancer</i> , 2006, 94, 1809-1815.	6.4	36
155	Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 34-39.	2.3	66
156	Molecular dynamics simulation and automated docking of the pro-apoptotic bax protein and its complex with a peptide designed from the Bax-binding domain of anti-apoptotic Ku70. <i>Journal of Cellular Biochemistry</i> , 2006, 99, 305-318.	2.6	28
157	Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN- γ in Head and Neck Cancer Cells In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 617-625.	7.0	88
158	Emerging anti-cancer molecular mechanisms of aminobisphosphonates. <i>Endocrine-Related Cancer</i> , 2006, 13, 7-26.	3.1	123
159	Targeting Raf-kinase: molecular rationales and translational issues. <i>Annals of Oncology</i> , 2006, 17, vii124-vii127.	1.2	27
160	Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 325-338.	4.3	64
161	EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 209-222.	1.6	8
162	Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. <i>Current Opinion in Oncology</i> , 2005, 17, 123-129.	2.4	8

#	ARTICLE	IF	CITATIONS
163	Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells. <i>Journal of Cellular Physiology</i> , 2005, 204, 539-548.	4.1	95
164	New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-?) treatment of human cancer. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 1-10.	4.2	81
165	A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications. <i>Annals of Oncology</i> , 2005, 16, 1980-1981.	1.2	2
166	Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased raf-1 ubiquitin-dependent degradation. <i>Cancer Biology and Therapy</i> , 2005, 4, 1159-1167.	3.4	20
167	Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications. <i>Current Drug Targets</i> , 2005, 6, 301-323.	2.1	56
168	Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways. <i>Current Drug Targets</i> , 2005, 6, 289-300.	2.1	15
169	Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase. <i>Current Drug Targets</i> , 2005, 6, 337-351.	2.1	33
170	The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and Pamidronate. <i>Oncogene</i> , 2004, 23, 6900-6913.	5.9	73
171	Expression of COX-2, mPGE synthase, MDR1 (P-gp), and Bcl-2; a molecular pathway of <i>H. pylori</i> -related gastric carcinogenesis. <i>Journal of Pathology</i> , 2004, 202, 305-312.	4.5	80
172	Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients. <i>Journal of Pathology</i> , 2004, 204, 317-325.	4.5	93
173	Alpha-Interferon and Its Effects on Signalling Pathways Within Cells. <i>Current Protein and Peptide Science</i> , 2004, 5, 475-485.	1.4	48
174	Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (Iressa?), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. <i>Journal of Cellular Physiology</i> , 2003, 195, 139-150.	4.1	127
175	EGF activates an inducible survival response via the RAS & Erk-1/2 pathway to counteract interferon-? mediated apoptosis in epidermoid cancer cells. <i>Cell Death and Differentiation</i> , 2003, 10, 218-229.	11.2	67
176	Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy. <i>Anti-Cancer Drugs</i> , 2001, 12, 489-497.	1.4	7
177	The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. <i>Amino Acids</i> , 2001, 20, 91-104.	2.7	66
178	Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. <i>Annals of Oncology</i> , 2000, 11, 339-342.	1.2	39
179	Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. <i>FEBS Journal</i> , 2000, 267, 3919-3936.	0.2	62
180	Cisplatin, raltitrexed, levofoinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: A phase II trial of the Southern Italy Cooperative Oncology Group (SICOG). <i>Annals of Oncology</i> , 2000, 11, 575-580.	1.2	8

#	ARTICLE	IF	CITATIONS
181	Post-Translational Modifications of Eukaryotic Initiation Factor-5A (eIF-5a) as a New Target for Anti-Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 1999, 472, 187-198.	1.6	33
182	Up-regulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMP. <i>FEBS Letters</i> , 1999, 447, 203-208.	2.8	4
183	Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. <i>Breast Cancer Research and Treatment</i> , 1998, 49, 13-26.	2.5	25
184	Molecular genetics of cancer. Oncogenes and tumor suppressor genes. <i>Cancer</i> , 1995, 76, 1869-1873.	4.1	8
185	Î±-interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. <i>International Journal of Cancer</i> , 1995, 61, 342-347.	5.1	36
186	cAMP-dependent protein kinase: role in normal and malignant growth. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 21, 33-61.	4.4	131
187	Point mutation of the autophosphorylation site or in the nuclear location signal causes protein kinase A RII beta regulatory subunit to lose its ability to revert transformed fibroblasts.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 10634-10638.	7.1	44
188	Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. <i>Anti-Cancer Drugs</i> , 1994, 5, 379-393.	1.4	18
189	Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 8884-8888.	7.1	24
190	Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. <i>Oncology Reports</i> , 0, , .	2.6	2
191	The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas. <i>International Journal of Oncology</i> , 0, , .	3.3	4